Loading...
Please wait, while we are loading the content...
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
| Content Provider | Scilit |
|---|---|
| Author | Ou, Sai-Hong Ignatius |
| Copyright Year | 2011 |
| Related Links | https://www.dovepress.com/getfile.php?fileID=11455 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232174/pdf |
| e-ISSN | 11778881 |
| DOI | 10.2147/dddt.s19045 |
| Journal | Drug design, development and therapy |
| Volume Number | 5 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2011-11-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Drug Design, Development and Therapy Hematology Pf-02341066 Anaplastic Lymphoma Kinase (alk) Crizotinib Non-small Cell Lung Cancer Rearrangement |
| Content Type | Text |
| Resource Type | Article |